Myotonic dystrophy type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs, including skeletal muscle, heart, brain and the ...

Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs including skeletal muscle, heart, brain and the ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...

One of the major highlights of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is that invaluable ...

Capricor Therapeutics’ investigational therapy deramiocel (CAP-1002) is being considered for approval in the U.S.

To benefit Muscular Dystrophy Association (MDA), the Grand Rapids Police Department and the Grand Rapids Fire Department will ...

Ifetroban demonstrated significant 5.4% improvement in cardiac functionNASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharma ...

Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.

NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today ...